|
|
| Research article summary (published 30 Oct 2006): |
|
Free Full Text! See links below |
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Full Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from dysregulation of the immune system. Interleukin-6 (IL-6) is a multifunctional cytokine produced by macrophages, monocytes and T and B cells. It stimulates B-cell differentiation/maturation, immunoglobulin secretion, and T-cell functions. Elevated levels of IL-6 in serum, urine and renal glomeruli were detected in patients with active SLE and in murine models of SLE. Our study investigated the role of IL-6 in an SLE-like disease in New Zealand Black/White (NZB/W) F1 mice by administration of an anti-murine IL-6 monoclonal antibody (mAb). Intraperitoneal administration of the anti-IL-6 mAb suppressed the production of anti-dsDNA autoantibody. B-cell proliferation induced by anti-IgM and anti-CD40 was lower in the anti-IL-6 mAb-treated mice, ex vivo studies demonstrated that anti-IL-6 mAb treatment inhibited anti-dsDNA production. Anti-CD3-induced T-cell proliferation and mixed lymphocyte reactions were inhibited by anti-IL-6 mAb treatment, indicating a partial down-regulation of T cells. Histological analysis showed that treatment with anti-IL-6 mAb prevented the development of severe kidney disease. These results suggest that treatment with anti-IL-6 mAb has a beneficial effect on autoimmunity in murine SLE and that autoreactive B cells may be the primary target for anti-IL-6 mAb treatment; its effect on autoreactive T cells is also indicated.
Learn Faster Today Improve your study skills
Author information
Author/s: Liang, Bailin (B); Gardner, Debra B (DB); Griswold, Don E (DE); Bugelski, Peter J (PJ); Song, Xiao Yu R (XY);
Affiliation: Immunobiology, Centocor, Radnor, PA, USA. bliang1(-atsign-)cntus.jnj.com
Journal and publication information
Publication Type: Journal Article
Journal: Immunology (Immunology), published in England. (Language: eng)
Reference: 2006-Nov; vol 119 (issue 3) : pp 296-305
Dates: Created 2006/10/27; Completed 2007/01/17; Revised 2008/11/20;
PMID: 17067309, status: MEDLINE (last retrieval date: 12/26/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
These are the highest related articles currently in the database:
- Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
30 Mar 2008 - Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
9 Mar 2008 - IgM antibodies against dsDNA in SLE.
30 May 2008 - Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice.
30 Jul 2008 - CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
29 Jun 2008 - B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
30 May 2008 - B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice.
30 Aug 2008 - A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
6 Apr 2008 - Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders.
30 May 2008 - Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
30 Jul 2008
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.